At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET
Dianthus Therapeutics raised approximately $719 million in gross proceeds through a public offering of 8.47 million common shares and pre-funded warrants for 402,468 additional shares, priced at $81.00 per share. The capital will fund clinical development, commercial readiness, and general corporate purposes, extending the company's runway but increasing potential dilution for existing shareholders.
- Closed public offering of 8,470,989 common shares and pre-funded warrants for 402,468 shares
- Offering price: $81.00 per share; pre-funded warrants priced at $80.999 with $0.001 exercise price
- Aggregate gross proceeds: ~$719 million before expenses
- Proceeds to fund clinical and preclinical programs, commercial readiness, and general corporate use
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access